Velaglucerase

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications

Bone involvement in Gaucher disease: Data from a North African registry.

Bone involvement in Gaucher disease: Data from a North African registry.

Journal: Reumatologia clinica
Published: July 17, 2025

Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience.

Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience.

Journal: Frontiers in pediatrics
Published: April 17, 2025

Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?

Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?

Journal: PharmacoEconomics - open
Published: April 08, 2025

Effective encapsulation of therapeutic recombinant enzyme into polymeric nanoparticles as a potential vehicle for lysosomal disease treatment.

Effective encapsulation of therapeutic recombinant enzyme into polymeric nanoparticles as a potential vehicle for lysosomal disease treatment.

Journal: International journal of biological macromolecules
Published: August 14, 2024

Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.

Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.

Journal: Journal of clinical medicine
Published: April 19, 2024

A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study.

A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study.

Journal: Journal of clinical medicine
Published: April 08, 2024

Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.

Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.

Journal: Journal of clinical medicine
Published: March 25, 2024

Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys.

Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys.

Journal: Orphanet journal of rare diseases
Published: March 12, 2024

Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey.

Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey.

Journal: Orphanet journal of rare diseases
Published: February 19, 2024

Impact of COVID-19 pandemic on healthcare delivery for lysosomal storage disorders at a tertiary care public hospital in Mumbai.

Impact of COVID-19 pandemic on healthcare delivery for lysosomal storage disorders at a tertiary care public hospital in Mumbai.

Journal: Journal of postgraduate medicine
Published: January 10, 2024

Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa.

Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa.

Journal: Journal of osteoporosis
Published: October 03, 2023

Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.

Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.

Journal: eLife
Published: March 08, 2023
Showing 1-12 of 97

Last Updated: 02/24/2026